SWOG clinical trial number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

Open
Phase
Accrual
21%
Abbreviated Title
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor…
Status Notes
This study is open to patient accrual effective 10/30/23.
Activated
10/30/2023
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Breast Cancer
Symptom Control and Quality of Life

Treatment

durvalumab

Patient Study Materials

Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
S2205

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy
Research Committee(s)
Symptom Control and Quality of Life
Activated
03/16/2023
Accrual
52%
Open
Phase
SWOG Clinical Trial Number
EAQ202

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Research Committee(s)
Symptom Control and Quality of Life
Activated
10/28/2021
Open
Phase
SWOG Clinical Trial Number
S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
Research Committee(s)
Symptom Control and Quality of Life
Activated
08/16/2021
Accrual
62%
Open
Phase